keyword
MENU ▼
Read by QxMD icon Read
search

Desvenlafaxine

keyword
https://www.readbyqxmd.com/read/29403141/desvenlafaxine-overdose-induced-toxic-cardiomyopathy-and-acute-left-ventricular-failure-a-case-report
#1
Sandeep Kumar Goyal, Chanchal Gera, Mamta Singla, Nitin Kumar
No abstract text is available yet for this article.
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29344746/desvenlafaxine-induced-interstitial-pneumonitis-a-case-report
#2
Arjan Flora, Daniel Pipoly
A 52-year-old man developed interstitial pneumonitis during treatment with desvenlafaxine for major depressive disorder. The man received desvenlafaxine at 50 mg for symptoms of depression 4 years earlier. Six months after a dose increase to 100 mg, he developed bronchitic symptoms with mild, persistent dyspnea. Investigations revealed a restrictive pattern on pulmonary function testing, bilateral upper lobe reticular opacities with traction bronchiectasis on radiology imaging, and end-stage interstitial fibrosis with honeycomb changes consistent with chronic hypersensitivity pneumonitis on open lung biopsy...
January 17, 2018: Drug Safety—Case Reports
https://www.readbyqxmd.com/read/29344340/assessment-and-management-of-sexual-dysfunction-in-the-context-of-depression
#3
REVIEW
Pratap R Chokka, Jeffrey R Hankey
Sexual dysfunction (SD) is pervasive and underreported, and its effects on quality of life are underestimated. Due in part to its bidirectional relationship with depression, SD can be difficult to diagnose; it is also a common side effect of many antidepressants, leading to treatment noncompliance. While physicians often count on patients to spontaneously report SD, treatment is optimized when the clinician instead performs a thorough assessment of sexual functioning before and during drug therapy using a standardized questionnaire such as the Arizona Sexual Experiences Scale (ASEX)...
January 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29327136/signal-detection-for-recently-approved-products-adapting-and-evaluating-self-controlled-case-series-method-using-a-us-claims-and-uk-electronic-medical-records-database
#4
Xiaofeng Zhou, Ian J Douglas, Rongjun Shen, Andrew Bate
INTRODUCTION: The Self-Controlled Case Series (SCCS) method has been widely used for hypothesis testing, but there is limited evidence of its performance for safety signal detection. OBJECTIVE: The objective of this study was to evaluate SCCS for signal detection on recently approved products. METHODS: A retrospective study covered the period after three recently marketed drugs were launched through to 31 December 2010 using The Health Improvement Network, a UK primary care database, and Optum, a US claims database...
January 11, 2018: Drug Safety: An International Journal of Medical Toxicology and Drug Experience
https://www.readbyqxmd.com/read/29228473/population-pharmacokinetics-of-desvenlafaxine-pharmacokinetics-in-korean-versus-us-populations
#5
Alice I Nichols, Sam Liao, Richat Abbas
Desvenlafaxine exposure in Korean and US populations was compared using population pharmacokinetic (PK) analysis. Data from a single- and multiple-dose study of desvenlafaxine (50, 100, and 200 mg) in 30 healthy Korean subjects were added to a population PK model previously developed using sparse PK samples from patients with major depressive disorder, including 140 Korean patients, combined with rich PK data from healthy volunteers. The structural PK model was an open 1-compartment linear disposition model with parallel first-order and 0-order inputs...
December 11, 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29189044/desvenlafaxine-versus-placebo-in-a-fluoxetine-referenced-study-of-children-and-adolescents-with-major-depressive-disorder
#6
Karen L Weihs, William Murphy, Richat Abbas, Deborah Chiles, Richard D England, Sara Ramaker, Dalia B Wajsbrot
OBJECTIVES: To evaluate the short-term efficacy and safety of desvenlafaxine (25-50 mg/d) compared with placebo in children and adolescents with major depressive disorder (MDD). METHODS: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening and baseline Children's Depression Rating Scale-Revised (CDRS-R) total scores >40 were randomly assigned to 8-week treatment with placebo, desvenlafaxine (25, 35, or 50 mg/d based on baseline weight), or fluoxetine (20 mg/d)...
November 30, 2017: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29185786/desvenlafaxine-versus-placebo-in-the-treatment-of-children-and-adolescents-with-major-depressive-disorder
#7
Sarah Atkinson, Shannon Lubaczewski, Sara Ramaker, Richard D England, Dalia B Wajsbrot, Richat Abbas, Robert L Findling
OBJECTIVE: To evaluate the short-term efficacy and safety of desvenlafaxine versus placebo in the treatment of children and adolescents with major depressive disorder (MDD). METHODS: Outpatient children (7-11 years) and adolescents (12-17 years) who met DSM-IV-TR criteria for MDD and had screening and baseline Children's Depression Rating Scale-Revised (CDRS-R) total scores >40 were randomly assigned to 8 weeks of treatment with placebo, low exposure desvenlafaxine (20, 30, or 35 mg/day based on baseline weight), or higher exposure desvenlafaxine (25, 35, or 50 mg/day based on baseline weight)...
February 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29170178/false-positive-phencyclidine-pcp-on-urine-drug-screen-attributed-to-desvenlafaxine-pristiq-use
#8
T Michael Farley, Emily N Anderson, Jade N Feller
We report a likely false-positive phencyclidine (PCP) result detected with a urine drug screen (UDS) (Medtox, St Paul, Minnesota, USA) in the setting of therapeutic desvenlafaxine (Pristiq) use. Desvenlafaxine (O-desmethylvenlafaxine) is the active metabolite of venlafaxine (Effexor). Prior reports have confirmed venlafaxine use resulting in a false-positive for PCP on a UDS. However, there has been a paucity of reporting of commercially available desvenlafaxine formulations (Pristiq, Khedezla) resulting in false-positives for PCP on a UDS...
November 23, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/29154157/efficacy-of-antidepressants-on-measures-of-workplace-functioning-in-major-depressive-disorder-a-systematic-review
#9
REVIEW
Yena Lee, Joshua D Rosenblat, JungGoo Lee, Nicole E Carmona, Mehala Subramaniapillai, Margarita Shekotikhina, Rodrigo B Mansur, Elisa Brietzke, Jae-Hon Lee, Roger C Ho, Samantha J Yim, Roger S McIntyre
INTRODUCTION: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD...
February 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29140227/categorical-improvement-in-functional-impairment-in-depressed-patients-treated-with-desvenlafaxine
#10
Claudio N Soares, Min Zhang, Matthieu Boucher
OBJECTIVE: This post-hoc pooled analysis evaluated categorical change in functional impairment in patients with major depressive disorder (MDD) treated with desvenlafaxine versus placebo and examined whether early improvement in functioning predicted functional outcomes at study endpoint. METHODS: Data were pooled from eight randomized, double-blind, placebo-controlled studies of desvenlafaxine for the treatment of MDD, including adults who were randomly assigned to receive desvenlafaxine 50 or 100 mg/d or placebo (N=3,384)...
November 15, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/29134498/vasoplegic-shock-treated-with-methylene-blue-complicated-by-severe-serotonin-syndrome
#11
Betty S Chan, Therese Becker, Angela L Chiew, Ahmed M Abdalla, Tom A Robertson, Xin Liu, Michael S Roberts, Nicholas A Buckley
INTRODUCTION: Management of severe vasoplegic shock in overdose can be very challenging. We describe a case of severe refractory vasodilatory shock in poisoning where methylene blue (MB) was used with success. However, the patient subsequently developed severe Serotonin Syndrome (SS) as a result of an interaction between serotonergic drugs and MB. CASE REPORT: A 15-year-old male developed severe vasoplegic shock 1.5 hours after overdosing on several different medications including quetiapine slow release, quetiapine immediate release, desvenlafaxine slow release, venlafaxine, amlodipine, ramipril, fluoxetine, promethazine and lithium...
November 13, 2017: Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology
https://www.readbyqxmd.com/read/29061415/antidepressant-related-jitteriness-syndrome-in-anxiety-and-depressive-disorders-incidence-and-risk-factors
#12
Preeti Sinha, Disha Jayaram Shetty, Laxminarayana K Bairy, Chittaranjan Andrade
INTRODUCTION: Jitteriness syndrome (JS) is a poorly understood but important adverse effect of antidepressant drugs. This study examined the incidence and pattern of antidepressant-related JS and its predictors. METHODS: 209 patients diagnosed with any anxiety or depressive disorder and started on mirtazapine, sertraline, desvenlafaxine, escitalopram or fluoxetine were assessed at baseline, after 2 weeks, and after 6 weeks with psychopathology rating scales and for predefined categories of JS...
October 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28951668/development-and-evaluation-of%C3%A2-desvenlafaxine-loaded-plga-chitosan-nanoparticles-for-brain-delivery
#13
Gui-Feng Tong, Nan Qin, Li-Wei Sun
Depression is a debilitating psychiatric condition that remains the second most common cause of disability worldwide. Currently, depression affects more than 4 per cent of the world's population. Most of the drugs intended for clinical management of depression augment the availability of neurotransmitters at the synapse by inhibiting their neuronal reuptake. However, the therapeutic efficacy of antidepressants is often compromised as they are unable to reach brain by the conventional routes of administration...
September 2017: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/28929323/what-type-and-dose-of-antidepressants-are-cancer-and-non-cancer-inpatients-being-prescribed-a-retrospective-case-control-study-at-an-australian-tertiary-hospital
#14
Saira Sanjida, Kelly Mulvogue, Joanne Shaw, Jeremy Couper, David Kissane, Sallie-Anne Pearson, Melanie A Price, Monika Janda
PURPOSE: Cancer patients are often prescribed antidepressants, but little data is available about whether the type and dose are similar to prescriptions to patients with other chronic diseases. This study compared the prescription practices of antidepressants to cancer and non-cancer inpatients at a major Australian tertiary hospital and assessed side effects and potential drug-drug interactions. METHODS: Inpatients diagnosed with cancer within the past 12 months and prescribed antidepressants were age and gender matched to inpatients with other chronic disease conditions...
September 19, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28888484/prediction-of-human-efficacious-antidepressant-doses-using-the-mouse-forced-swim-test
#15
Eunice Yuen, Steven Swanson, Jeffrey M Witkin
The forced swim test (FST) is a commonly used preclinical animal behavioural model for prediction of antidepressant activity in humans. While the FST may qualitatively predict efficacy, less is known about the quantitative translation of FST data to human efficacious doses. Assessing quantitative translation allows better predictions of human efficacious doses and a higher chance of success in the drug development process. Dose-response and time-course FST experiments were carried out on mice using four marketed antidepressants (citalopram, desipramine, bupropion, desvenlafaxine) in addition to ketamine, all with varying mechanisms of action...
October 2017: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/28827861/the-prospective-24-week-assessment-of-cost-efficacy-of-and-compliance-to-antidepressant-medications-in-a-rural-setting-pacecar-study
#16
T S Sathyanarayana Rao, J Shivanand Manohar, Rajesh Raman, M S Darshan, Abhinav Tandon, K N Karthik, N Saraswathi, Keya Das, G T Harsha, Swetha Patil Kunkeri, Chittaranjan Andrade
BACKGROUND: Anxiety and depression are common mental health disorders that are responsible for considerable societal burden. There are no data on cost-efficacy and medication compliance related to the treatment of these disorders in rural India. MATERIALS AND METHODS: All consenting adults (n = 455) diagnosed with generalized anxiety or (unipolar) depressive disorders in Suttur village, Karnataka, were treated with open-label fluoxetine (20-60 mg/day), sertraline (50-150 mg/day), escitalopram (10-20 mg/day), desvenlafaxine (50-150 mg/day), duloxetine (30-90 mg/day), amitriptyline (75-150 mg/day), or clomipramine (75-150 mg/day) in a structured, monotherapy dosing plan...
April 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/28817491/speed-of-improvement-in-symptoms-of-depression-with-desvenlafaxine-50-mg-and-100-mg-compared-with-placebo-in-patients-with-major-depressive-disorder
#17
Martin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, Ellen Meier, Rita Prieto, Elizabeth Pappadopulos, Joan Mackell, Matthieu Boucher
PURPOSE/BACKGROUND: This post hoc analysis examined the time point at which clinically significant improvement in major depressive disorder (MDD) symptoms occurs with desvenlafaxine versus placebo. METHODS: Data were pooled from 9 short-term, double-blind, placebo-controlled studies in adults with MDD randomly assigned to desvenlafaxine 50 mg/d, 100 mg/d, or placebo. A mixed-effects model for repeated-measures analysis of change from baseline score was used to determine the time point at which desvenlafaxine treatment groups separated from placebo on the 17-item Hamilton Rating Scale for Depression and psychosocial outcomes...
October 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28803957/a-standardization-of-the-novelty-suppressed-feeding-test-protocol-in-rats
#18
Arantxa Blasco-Serra, Eva M González-Soler, Ana Cervera-Ferri, Vicent Teruel-Martí, Alfonso A Valverde-Navarro
Tests based on hyponeophagia phenomena are the most widely used to check the efficacy and efficiency of new-generation chronic antidepressant treatments. Even so, these tests lack strict consensus about their methodology, which reduces their validity, reproducibility and makes translatability difficult. Therefore, after an extensive literature review on this subject, we propose a methodological protocol for the Novelty-Suppressed Feeding Test to normalize this situation. Animals were induced to a reserpine-induced depression model and were then chronically treated with duloxetine, desvenlafaxine or vehicle...
September 29, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28763345/risk-of-hair-loss-with-different-antidepressants-a-comparative-retrospective-cohort-study
#19
Mahyar Etminan, Mohit Sodhi, Ric M Procyshyn, Michael Guo, Bruce C Carleton
The aim of this study was to quantify the risk of hair loss with different antidepressants. A retrospective cohort study design using a large health claims database in the USA from 2006 to 2014 was utilized. A cohort of new user and mutually exclusive users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion were followed to the first diagnosis of alopecia. The cohort was comprised of 1 025 140 new users of fluoxetine, fluvoxamine, sertraline, citalopram, escitalopram, paroxetine, duloxetine, venlafaxine, desvenlafaxine, and bupropion, with sertraline the most commonly prescribed (N=190 227) and fluvoxamine (N=3010) the least prescribed...
July 31, 2017: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28763344/the-impact-of-fatigue-and-energy-on-work-functioning-and-impairment-in-patients-with-major-depressive-disorder-treated-with-desvenlafaxine
#20
David Sarfati, Vanessa C Evans, Edwin M Tam, Cindy Woo, Grant L Iverson, Lakshmi N Yatham, Raymond W Lam
Fatigue and low energy are cardinal symptoms of major depressive disorder (MDD) that have an impact on work functioning. Antidepressants with noradrenergic activity have been hypothesized to improve symptoms of fatigue and low energy. We examined the impact of these symptoms on work functioning in patients with MDD treated with the serotonin and noradrenaline reuptake inhibitor, desvenlafaxine. A secondary analysis was carried out from a study of employed adult outpatients (n=35) with MDD and subjective cognitive complaints treated with desvenlafaxine 50-100 mg/day for 8 weeks...
November 2017: International Clinical Psychopharmacology
keyword
keyword
48023
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"